Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 2/20 | 0.39 |
| ▸ | RIN1 | Q13671 | 2/20 | 0.39 |
| ▸ | NT5E | P21589 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.33 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.33 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.33 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.33 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.32 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.31 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.31 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL837609 | 0.89 | POLB (0.38) | POLBABL1RIN1NT5EMEN1 | |
| SCHEMBL836805 | 0.88 | POLB (0.37) | POLBABL1RIN1NT5EMEN1 | |
| SCHEMBL838370 | 0.87 | POLB (0.36) | POLBABL1RIN1NT5EMEN1 | |
| SCHEMBL874315 | 0.83 | POLB (0.49) | POLBABL1RIN1NT5EP2RY2 | |
| SCHEMBL12197508 | 0.79 | POLB (0.43) | POLBABL1RIN1NT5EP2RY2 | |
| SCHEMBL4704898 | 0.78 | POLB (0.37) | POLBABL1RIN1NT5EP2RY2 | |
| SCHEMBL835719 | 0.78 | POLB (0.46) | POLBABL1RIN1NT5EMEN1 | |
| SCHEMBL22625658 | 0.77 | POLB (0.53) | POLBABL1RIN1NT5E | |
| SCHEMBL16350596 | 0.75 | POLB (0.40) | POLBABL1RIN1NT5EP2RY2 | |
| SCHEMBL837389 | 0.75 | POLB (0.40) | POLBABL1RIN1NT5EP2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143396-B2 | 1-[2′, 3′ -dideoxy-3′ C- (hydroxymethyl)—beta-D-erythro-pentofuranosyl] cytosine derivatives as HIV inhibitors | MEDIVIR AB (SE) | 2012-03-27 | — | — | US | disclosed |
| US-20110112294-A1 | 1-[2', 3' -DIDEOXY-3' C- (HYDROXYMETHYL) - BETA-D-ERYTHRO-PENTOFURANOSYL] CYTOSINE DERIVATIVES AS HIV INHIBITORS | MEDIVIR AB (SE) | 2011-05-12 | — | — | US | disclosed |
| US-7888367-B2 | reverse transcriptase mutants which allow an obligate chain terminating nucleoside- or nucleotide phosphate to be excised from the nascent DNA strand by ATP- or pyrophosphate-mediated excision | MEDIVIR AB (SE) | 2011-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112294-A1 | 1-[2', 3' -DIDEOXY-3' C- (HYDROXYMETHYL) - BETA-D-ERYTHRO-PENTOFURANOSYL] CYTOSINE DERIVATIVES AS HIV INHIBITORS | NUDT1, RRM2, TYMP | POLB 16/4885ABL1 4053/4885RIN1 779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.